Cancer Research Meeting Calendar  Protein Translation and Cancer
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Russell, J. S.
Right arrow Articles by Tofilon, P. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Russell, J. S.
Right arrow Articles by Tofilon, P. J.
[Cancer Research 62, 2318-2326, April 15, 2002]
© 2002 American Association for Cancer Research


Experimental Therapeutics

Inhibition of Radiation-induced Nuclear Factor-{kappa}B Activation by an Anti-Ras Single-Chain Antibody Fragment

Lack of Involvement in Radiosensitization

Jeffery S. Russell, Uma Raju, Glenice J. Gumin, Fredrick F. Lang, Deborah R. Wilson, Thierry Huet and Philip J. Tofilon1

Molecular Radiation Therapeutics Branch, Radiation Oncology Science Program, National Cancer Institute, Bethesda, Maryland 20892 [J. S. R., P. J. T.]; Departments of Experimental Radiation Oncology [J. S. R., U. R., G. J. G., P. J. T.] and Neurosurgery [F. F. L., P. J. T.], The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030; Introgen Therapeutics, Inc., Houston, Texas 77054 [D. R. W.]; and Aventis Pharmaceuticals, Hayward, California 94540 [T. H.]

We have shown previously that the transduction of a number of human tumor cell lines with an adenovirus (AV1Y28) expressing a single-chain antibody fragment (scFv) directed against Ras proteins results in radiosensitization. Because Ras is involved in the regulation of a number of transcription factors, we have determined the effects of this adenovirus on the activation of nuclear factor-{kappa}B (NF-{kappa}B), a radiation-responsive transcription factor associated with cell survival. In U251 human glioma cells, radiation-induced NF-{kappa}B was significantly attenuated by prior transduction of the anti-Ras scFv adenovirus. This effect appeared to involve an inhibition of I{kappa}B kinase activity and I{kappa}B{alpha} phosphorylation. Inhibitors to the Ras effectors mitogen-activated protein kinase kinase, phosphatidylinositol 3-kinase, and p38, however, did not reduce radiation-induced NF-{kappa}B. Whereas AV1Y28 inhibited NF-{kappa}B activation by hydrogen peroxide and ferricyanide, it had no effect of tumor necrosis factor-{alpha}-induced NF-{kappa}B activation. These results are consistent with a novel Ras-dependent, oxidant-specific signaling pathway mediating the activation of NF-{kappa}B. In additional cell lines radiosensitized by AV1Y28, radiation-induced NF-{kappa}B activation was also inhibited by the anti-Ras scFv, whereas in cell lines not radiosensitized, radiation did not activate NF-{kappa}B. This correlation suggested that AV1Y28-mediated radiosensitization involved the inhibition of radiation-induced NF-{kappa}B activation. However, inhibition of NF-{kappa}B activation via the expression of a dominant-negative form of I{kappa}B{alpha} in U251 cells had no effect on radiation-induced cell killing and did not influence AV1Y28-mediated radiosensitization. Therefore, whereas AV1Y28 inhibits radiation-induced NF-{kappa}B activation, this process does not appear to play a direct role in its radiosensitizing actions.




This article has been cited by other articles:


Home page
Clin. Cancer Res.Home page
S. Kunigal, S. S. Lakka, P. Joseph, N. Estes, and J. S. Rao
Matrix metalloproteinase-9 Inhibition Down-Regulates Radiation-Induced Nuclear Factor-{kappa}B Activity Leading to Apoptosis in Breast Tumors
Clin. Cancer Res., June 1, 2008; 14(11): 3617 - 3626.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
K. Camphausen and P. J. Tofilon
Inhibition of Hsp90: A Multitarget Approach to Radiosensitization
Clin. Cancer Res., August 1, 2007; 13(15): 4326 - 4330.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
H. Dote, D. Cerna, W. E. Burgan, K. Camphausen, and P. J. Tofilon
ErbB3 Expression Predicts Tumor Cell Radiosensitization Induced by Hsp90 Inhibition
Cancer Res., August 1, 2005; 65(15): 6967 - 6975.
[Abstract] [Full Text] [PDF]


Home page
CarcinogenesisHome page
B. Y. Kim, K. A. Kim, O. Kwon, S. O. Kim, M. S. Kim, B. S. Kim, W. K. Oh, G. D. Kim, M. Jung, and J. S. Ahn
NF-{kappa}B inhibition radiosensitizes Ki-Ras-transformed cells to ionizing radiation
Carcinogenesis, August 1, 2005; 26(8): 1395 - 1403.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
R. W. Caron, A. Yacoub, X. Zhu, C. Mitchell, S. I. Han, T. Sasazuki, S. Shirasawa, M. P. Hagan, S. Grant, and P. Dent
H-RAS V12-induced radioresistance in HCT116 colon carcinoma cells is heregulin dependent
Mol. Cancer Ther., February 1, 2005; 4(2): 243 - 255.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
R. W. Caron, A. Yacoub, M. Li, X. Zhu, C. Mitchell, Y. Hong, W. Hawkins, T. Sasazuki, S. Shirasawa, A. P. Kozikowski, et al.
Activated forms of H-RAS and K-RAS differentially regulate membrane association of PI3K, PDK-1, and AKT and the effect of therapeutic kinase inhibitors on cell survival
Mol. Cancer Ther., February 1, 2005; 4(2): 257 - 270.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
K. Camphausen, K. J. Brady, W. E. Burgan, M. A. Cerra, J. S. Russell, E. E.A. Bull, and P. J. Tofilon
Flavopiridol enhances human tumor cell radiosensitivity and prolongs expression of {gamma}H2AX foci
Mol. Cancer Ther., April 1, 2004; 3(4): 409 - 416.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
J. S. Russell, K. Brady, W. E. Burgan, M. A. Cerra, K. A. Oswald, K. Camphausen, and P. J. Tofilon
Gleevec-Mediated Inhibition of Rad51 Expression and Enhancement of Tumor Cell Radiosensitivity
Cancer Res., November 1, 2003; 63(21): 7377 - 7383.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
J. S. Russell, W. Burgan, K. A. Oswald, K. Camphausen, and P. J. Tofilon
Enhanced Cell Killing Induced by the Combination of Radiation and the Heat Shock Protein 90 Inhibitor 17-Allylamino-17- Demethoxygeldanamycin: A Multitarget Approach to Radiosensitization
Clin. Cancer Res., September 1, 2003; 9(10): 3749 - 3755.
[Abstract] [Full Text] [PDF]


Home page
CarcinogenesisHome page
C. L. Crowley-Weber, C. M. Payne, M. Gleason-Guzman, G. S. Watts, B. Futscher, C. N. Waltmire, C. Crowley, K. Dvorakova, C. Bernstein, M. Craven, et al.
Development and molecular characterization of HCT-116 cell lines resistant to the tumor promoter and multiple stress-inducer, deoxycholate
Carcinogenesis, December 1, 2002; 23(12): 2063 - 2080.
[Abstract] [Full Text] [PDF]


Home page
Mol. Biol. CellHome page
J. S. Russell and P. J. Tofilon
Radiation-induced Activation of Nuclear Factor-kappa B Involves Selective Degradation of Plasma Membrane-associated Ikappa Balpha
Mol. Biol. Cell, October 1, 2002; 13(10): 3431 - 3440.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2002 by the American Association for Cancer Research.